-+ 0.00%
-+ 0.00%
-+ 0.00%

Cordis says SELUTION4SFA trial shows 90.3% 12-month primary patency for SUSTANE drug-eluting balloon

PUBT·10/06/2026 13:35:08
Cordis says SELUTION4SFA trial shows 90.3% 12-month primary patency for SUSTANE drug-eluting balloon
  • Cordis reported that its SELUTION SLR SUSTANE PTA drug-eluting balloon delivered strong 12-month performance in the SELUTION4SFA pivotal study.
  • Results were presented at VIVA 2026 in a Late-Breaking Clinical Trial session.
  • The trial met its main efficacy goal, supporting a case for the device as an alternative to standard balloon angioplasty.
  • Data are intended to underpin an FDA filing, positioning Cordis to pursue a first US approval for a sirolimus drug-eluting balloon in femoropopliteal disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cordis Corporation published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.